Introduction
============

The insights of the genome have changed overwhelmingly over the past decades. It has been a long time before we realize our unawareness of microcosm. There is no doubt that the advent of sensitive, high-throughput sequencing (NGS) has given rise to an unheard-of ability to detect novel transcripts [@B1]. Those "nonsense and dark materials of genome" unravel their mystery, play more important roles, and participate in various biological processes. However, those discoveries don\'t mean the end, but seem to open a door to take us toward a more in-depth research on microcosm. Until now, except for messengers RNA (mRNA) and other functional RNAs, such as transfer RNA (tRNA), small nuclear RNA (snRNA), small nucleolar (snoRNA), and micro RNA (miRNA), we know very little on how lncRNAs function, how many different types of lncRNAs exist, or even whether most of them carry biological significance [@B1]. This review focused on the basic research of lncRNAs and their medical applications in human cancer and cardiovascular diseases.

Definition and classification of lncRNAs
========================================

The present definition of lncRNA, that is, an RNA molecule with a size longer than 200 nucleotides that is not translated into a protein, may be arbitrary without considering the following two issues [@B2]. 1). About the molecular size: A cutoff of 200 nucleotides was more based on the principle of RNA binding acid to silica columns during RNA purification [@B3]. While a protein coding gene (PCG) is usually defined as a transcript that contains an open reading frame (ORF) longer than 100 amino acids [@B4], thus a lncRNA might contain a longer ORF but not synthesize polypeptides. Besides, polypeptides shorter than 100 amino acids can be functional in organisms and are not outgrowth of canonical proteins [@B5]. 2) About the functions: The same RNA can contain both PCG and non-coding functions [@B6]. Coding transcript can lose their ability to encode a protein, and noncoding transcripts can acquire a coding function [@B6]. Such above issues obscures a clear annotation of lncRNAs. The definition by Mercer et al is more moderate, who defined lncRNAs as RNA molecules that may function as either primary or spliced transcripts and could not be classified into known classes of small RNAs or structural RNAs [@B7]. Compared with small ncRNAs, such as miRNAs, which have been defined in more detail and comprehensively, the definition of lncRNA is still extensive with complex contexts. However, finally some difference has been made following an in-depth research of lncRNAs.

LncRNAs constitute various RNA molecules. It is difficult to classify them because of their broad spectrum of molecular splicing and cellular functions as a result of implementing different modes of action. The traditional classification is based on their locations of transcripts from genome, including five broad categories: (1) sense, (2) antisense, (3) bidirectional, (4) intronic, and (5) intergenic [@B8]. However, as new forms of lncRNAs were continually being found, the traditional classification of lncRNA could not cover the whole field and should be described in more detail. Sandre et al., who viewed it more widely, classified lncRNAs into eight categories: (A) divergent (pancRNA: They originate from the opposite strand of the same promoter region of protein coding gene as the adjacent) and convergent (They encoded on the opposite strands and facing each other); (B) intronic (They transcribed from an intron of another gene); (C) intergenic (They located distant from other genes, usually \>10kb); (D) overlapping sense (They overlapped with other genes on the same strand) and overlapping antisense (They overlapped with other genes on the opposite strand); (E) enhancer RNA (They expressed as uni- or bidirectional transcripts); (F) miRNA host gene (Figure [1](#F1){ref-type="fig"}) [@B9]. Compared with the former classification, the latter described the relationship between lncRNA gene and their neighborhood gene in detail. However, they still belong to one criterion in essence. Following the development of new forms of lncRNAs, the classification needs to be continuously improved taking more criteria into account, such as their splicing modes or their final working mechanisms.

Research methods and strategies of lncRNAs
==========================================

Unlike miRNAs, which have been extensively studied, the research of lncRNAs is still in its infancy. The following sections discuss four research strategies of lncRNAs with several common methods for each strategy (Figure [3](#F3){ref-type="fig"}): (1) new species identification, (2) subcellular localization, (3) molecular interaction, and (4) gain of loss of function and (5) bioinformatics analysis.

New species identification
--------------------------

Although some difficulties exist in terms of lncRNA discovery because of tissues specificity and low expression levels, many kinds of methods still exist for identifying new lncRNAs, which were well reviewed by Kashi et al. [@B10]. Each kind of technology was used to certain purpose. Among them, RNA-seq might be the most wide-spread method used not only for RNA expression detection but also for novel lncRNA discovery [@B10]. Sometimes, because of limited samples sizes for RNA-seq, single-cell transcript sequencing were needed, including Smart-Seq, which allows the detection of alternative transcripts isoforms and single-nucleotide polymorphisms [@B11]; DP-Seq, which allows amplification of RNA from sample sizes as small as 50pg [@B10]; and Quartz-Seq, which reduces the background noise [@B12]. Besides, some methods could be used to map transcripts that are in the process of being degraded, including PARE-Seq [@B13], GMUCT [@B14], and Degradome-Seq [@B15], by which decapped transcripts are adapter ligated and reverse transcribed [@B10].

Subcellular localization
------------------------

Fluourescence in situ hybridization (FISH) is a method for visualization the subcellular localization of a certain lncRNA. For example, MALAT1 has been visualized by RNA-FISH, which indicated that it is rich in nuclear speckles of cells in interphase and is concentrated in mitotic interchromain granule clusters [@B16]. RNA-FISH was used to verify that MIR99HG (MONC) and MIR100HG were located in the nucleus [@B17]. Furthermore, RNA-FISH could also be combined with DNA-FISH to validate co-localization of a transcript with chromatin sequences [@B10].Alternatively, new recent technology of fluorescent in situ RNA sequencing (FISSEQ), which amplify cDNA in crosslinked cells and tissue samples [@B18], provide higher resolution and can identify a higher number of targets than RNA-FISH [@B10].

Molecular interaction
---------------------

On the basis of the working mechanisms of lncRNAs, molecular interactions occur among RNA, DNA, and proteins. The related technologies can also be classified into three categories: (1) RNA-protein interaction: RNA immunoprecipitation is used to analyze and purify RNAs associated with specific proteins by directing antibodies against the target protein [@B10]. High-throughput sequencing cross-linking immunoprecipitation (HITS-CLIP/ CLIP-Seq) is another technique to analyze the interaction between RNA and protein by cross-linking cell in vitro with UV light [@B10]. (2) RNA-DNA interaction: chromatin isolation by RNA purification (ChIRP) can analyze the relationship between RNA and chromatin by 20 nt-long biotinylated oligonucleotides which specifically recognize the target lncRNA [@B19]; RNA antisense purification (RAP) is another method which can be used to identify the genomic regions of chromatin that interact with RNAs using about 120nt long antisense RNA probes[@B20]; capture hybridization analysis of RNA targets (CHART) involves the purification of cross-linked protein, RNA, and DNA complexes by designing its probe on the region of potential open binding sites [@B10], [@B21]. (3) RNA and RNA interaction: rap-rna modification of the RAP method can provide a means to detect RNA-RNA interactions, even to distinguish the direct and indirect interaction between RNA transcripts by using different cross-linking methods [@B10]; Cross-linking, ligation and sequencing of hybrids (CLASH) is another technology for capturing direct RNA and RNA interaction by using UV cross-linking [@B22].

Gain or loss of function
------------------------

Traditionally, if we want to learn about the function of a new molecule, we generally over-express or knock down the candidate target to investigate changes resulted by these means. LncRNAs could also follow the above methods. For example, using over-expression plasmid and siRNA (or shRNA) separately to up regulating and down regulating lncRNA, Cui et al., have verified that over-expression of HULC was able to accelerate lipogenesis in HepG2 and Huh7 cells, while HULC siRNA attenuate the lipogenesis in HepG2.2.15 cells [@B23]. For another, using the same methods, Nie et al., have found that knockdown of ANRIL expression could impair cell proliferation and induce cell apoptosis both in vitro and vivo [@B24]. In fact, in order to gain stable function of a gene, technology of lentivirus has been used for many years. Presently, although there has always been a dispute, exact gene editing techonologies, such as CRISPR/CAS9 and NgAgo have emerged. Compared to the traditionally methods, they might be expected to realize the more accurate gene editing than any time in the past.

Bioinformatics analysis
-----------------------

The lncRNA databases have grown rapidly following with the research of lncRNAs. The database of lncRNAdb (<http://www.lncrnadb.org/>) is a famous long non-coding RNA research database that provides full comments on functional lncRNAs [@B25]. The present version is lncRNAdb 2.0 [@B26]. Another well-known ncRNA research database NONCODE (<http://www.noncode.org>) also provides full comments on lncRNAs, including expression and functions predicted by their computer software (ncFANs) [@B27]. Now the version has been updated to NONCODE v4 [@B28]. LNCipedia (<http://www.lncipedia.org>) provides the sequence and full comments on structures of human lncRNAs[@B29]-[@B30]. LncRNA disease (<http://cmbi.bjmu.edu.cn/lncrnadisease>) provides full comments of reported disease-related lncRNAs[@B31]. NRED (<http://jsm-research.imb.uq.edu.au/nred/>) provides the lncRNA expression information of human and mouse based on chip data [@B32]. ChIPBase (<http://deepbase.sysu.edu.cn/chipbase/>) provides the map of lncRNA, comprehensive identification, and annotation of the transcription regulation [@B33]. It also integrated lncRNAs identified by high-throughput RNA-seq, their expression profile and even the transcription factor binding sites identified by ChIP-seq experiment [@B33]. fRNAdb (<http://www.ncrna.org/>) collects non-code transcripts with or without comments from H-invitation, NONCODE and RNAdb database and provides searching function of four kinds of ncRNAs, including miRNAs, short ncRNAs, mid-size ncRNAs and lncRNAs [@B34]. Starbase (<http://starbase.sysu.edu.cn/mirLncRNA.php>) has set up the most comprehensive experimental support by CLIP-Seq for the regulation network of miRNA and lncRNA, Protein (RNA-binding protein) and lncRNA (includes lncRNA, pseudogene, circular RNA), competing endogenous RNAs (ceRNA) regulatory networks and provides prediction tools for a lncRNA function [@B35]. In fact, the section of bioinformatics analysis should not be summarized as a separate section because the context of each of the aforementioned sections could be permeated with biological information. Necessary information can be searched before studying a new function of a known lncRNA, or more information can be supplemented after the research on a new lncRNA.

Working mechanisms of lncRNAs
=============================

LncRNAs play important regulatory roles and participate in different levels of biological processes, such as chromatin remodeling, histone modification, and DNA methylation, and also serve as transcription factors or enhancers. The mechanisms underlying their functions can be summarized as interactions among RNA, DNA, and proteins (Figure [2](#F2){ref-type="fig"}). These interactions can be further summed up into two modes: (1) based on sequence hybridization and (2) based on secondary or tertiary structures.

Interaction based on specific sequence hybridization
----------------------------------------------------

Some lncRNAs can mediate interactions by specific sequence hybridization with DNAs or other RNAs. For example, antisense intronic noncoding ras association domain family member 1 (ANRASSF1), which is transcribed in the antisense direction relative to the protein-coding mRNAs of the RAS association domain family member 1 (RASSF1) gene locus, could interact with genomic DNA, forming an RNA-DNA hybrid and regulating the expression of the sense gene at the pre-transcriptional level[@B36]. Phosphatase and tensin homolog pseudogene 1 antisense RNA (PTENP1-AS) may be an example of the RNA-RNA interaction. Because of the lack of a poly(A) tail, the stability and export to the cytoplasm of phosphatase and tensin homolog pseudogene 1 (PTENP1) is facilitated by interactions with PTENP1-AS, which has three variants: alpha, beta, and unspliced [@B37]. During this process, PTENP1-AS beta forms an RNA-RNA duplex with the PTENP1 transcript, altering its subcellular distribution and increasing its RNA stability [@B6], [@B37].

If the aforementioned examples of interaction between lncRNA and other RNAs are a universal phenomenon, the discovery of competing endogenous RNA (ceRNA) function of lncRNAs, which is of great biological significance, will not be surprising. LncRNAs can participate in the ceRNA network, by which lncRNAs cross talk with other RNAs by sharing the same miRNAs [@B38]. These exogenously expressed transcripts contain tandem repeats of miRNA response elements (MRE) sites that allow them to specifically bind a distinct miRNA or combination of miRNAs [@B39]. Once the miRNA(s) of interest is decoyed, it is unavailable to bind to its targets, leading to effective derepression of these transcripts [@B40], [@B41]. Such ceRNA function of lncRNAs has been well studied in human cancers. Metastasis-associated lung adenocarcinoma transcript 1(MALAT1) could sponge miR-145 to modulate the radio-sensitivity of high-risk human papillomavirus (HR-HPV+) cervical cancer [@B42]. Liu S. et al., reported that MALAT1 could competitively bind with miR-124 to up-regulate the RBG2 expression, and then promote HR-HPV (+) cervical cancer cell growth and invasion [@B43]. HOX transcript antisense RNA (HOTAIR) could cross talk with erb-b2 receptor tyrosine kinase 2 (HER2kny) via miR-331-3p in gastric cancer [@B44]. Li JT. et al., identified that HOTAIR could suppress the miR-568 to up-regulate the expression of S100 calcium binding protein A1 (S100A), and then facilitates the metastasis of breast cancer [@B45]. The B-Raf proto-oncogene, serine/threonine kinase (BRAF) pseudogene 1 is a newly reported lncRNA that functions as a ceRNA for BRAF, in part by sponging miR-30a, miR-182, and miR-876[@B46].

Interaction based on secondary and tertiary structures
------------------------------------------------------

LncRNAs can also form secondary and tertiary structures that enable more complex interactions with proteins. For example, cyclin-dependent kinase inhibitor 2B antisense RNA 1(ANRIL) was identified to recruit polycomb repressive complex-1 (PRC1) and polycomb repressive complex-2 (PRC2) to form heterochromatin surrounding the INK4b-ARF-INK4a locus, and to repress gene expression [@B47]. Similarly, imprinted maternally expressed transcript (H19) could interact with the protein complex heterogeneous nuclear ribonucleoprotein U/lysine acetyltransferase 2B/RNA polymerase II (hnRNP U/PCAF/RNAPol II), activating miR-200 family by increasing histone acetylation, and then altering the miR-200 pathway, thus contributing to mesenchymal-to-epithelial transition and suppression of tumor metastasis in hepatocellular carcinoma (HCC) [@B48]. Moreover, MALAT1 could promote cell proliferation, migration, and invasion via PRKA kinase anchor protein 9 (AKAP-9) in gastrointestinal cancer [@B49]. It also could combine with splicing factor proline/glutamine-rich (SFPQ) to release polypyrimidine tract binding protein 2 (PTBP2) from the SFPQ/PTBP2 complex to promote the growth and metastasis of colon cancer [@B50]. Besides, tumor protein p53 pathway corepressor 1 (TP53COR1/LincRNA-p21) recruits heterogeneous nuclear ribonucleoprotein K (hnRNP-K) to the promoter of p21, which is pivotal for the efficient binding of p53 to the p21 promoter to initialize the transcription of p21, such that lincRNA-p21 could activate the expression of p21 [@B51].

Although the interaction mechanisms were identified, in many cases, each interaction could not exist independently; they always worked together. Considering the aforementioned context as an example, the working mechanisms of lincRAN-p21 could be summarized as a mode of lincRNA-p21(lncRNA)-p53(protein) promoter of p21(DNA) interaction.

Functions of lncRNAs during the embryogenesis and organ differentiation
=======================================================================

lncRNA transcripts were found at all examined stages during the early differentiation process by a single-cell sequencing study [@B52]. Furthermore, in the following various differentiation periods, they might also act as important functions. In this section, we would like to discuss several lncRNAs involved in the embryogenesis and organ differentiation.

Imprinted genes are monoallelically expressed according to the parent of origin and are critical for embryogenesis [@B53]. *H19*is a well-known imprinted gene, which is exclusively expressed from the maternal allele and governs normal embryogenesis [@B54]. Maternally expressed 3 (*meg3*) is another imprinted gene, which has effects on neighboring genes in cis and results in perinatal lethality [@B55].

X-chromosome inactivation (XCI) is also an interesting phenomenon during embryogenesis. *Xist* was found as an XCI gene in knockout mice two decades ago [@B56]-[@B57]. Lacking *Xist* could cause female mice die during the first half of gestation, while male mice were unaffected [@B9]. However, knockout female mice with a single X-chromosome (XO) lacking *Xist* could survive [@B9]. Thus, it can be explained by the failure to adjust the X-chromosome gene dosage and causes embryonic lethality [@B9].

There are so many kinds of lncRNAs related to various organ differentiations that we could not cover them all. However, we would like to focus more about on lncRNAs related to cardiovascular differentiation.

*Fendrr* is an example of lncRNAs demonstrated to play an essential role in cardiovascular differentiation and embryo survival [@B9]*.* Grote et al. have verified that loss of *Fendrr*lead to impaired differentiation of tissues derived from lateral mesoderm, the heart and the body wall, and eventually result in embryonic death [@B58]-[@B59]. Embryos lacking *Fendrr* lead to upregulation of some transcription factors which controlled lateral plate or cardiac mesoderm differentiation, coupled with a drastic reduction in PRC2 occupancy along with decreased H3K27 trimethylation and/or an increase in H3K4 trimethylation at their promoters [@B59].

*Braveheart* (*Bvht*) has been verified as another cardiac-expressed lncRNA [@B60]. It epigenetically regulates cardiomyocyte differentiation [@B61]. It was cardiac-enriched approximately threefold than other tissues, but expressed similar with E14.5 embryos and adults; It was also not regulated late after hemodynamic stress [@B60]. In addition to its canonical role in regulation of MesP1, it may play "housekeeping" roles in adult hearts to stimulate and maintain cardiomyocyte fate [@B60].

*Kcnq1ot1* induces transcriptional silencing by histone methylation of the overlapping *Kcnq1/Kv7.1* potassium channel gene and other genes at the same genomic locus [@B62]-[@B64]. It is expressed at high levels in embryonic hearts, but reduced 5 times in adult hearts. Its counterparts mRNA, Kcnq1, which encodes the Kv7.1 slow delayed rectifying potassium channel increased during the same period. Kcnq1 is vital for normal cardiomyocyte repolarization which ends the action potential and cardiomyocyte contraction. Such a combination of opposite changes, in accordance with the need for enhanced pump function during the transition between developing embryonic and fully functioning adult hearts.

By using RNA-sequencing, Kurian et al. have identified 3 previously uncharacterized lncRNAs, *TERMINATOR, ALIEN,*and*PUNISHER*, which were specifically expressed in undifferentiated pluripotent stem cell, cardiovascular progenitors, and differentiated endothelial cell, respectively [@B65]. They provide a comprehensive transcriptomic roadmap that sheds new light on the molecular mechanisms underlying human embryonic development, mesodermal commitment, and cardiovascular specidication [@B65]. By the same method, Matkovich et al. identified 321 lncRNAs present in the heart and 117 of which exhibit a cardiac-enriched pattern of expression [@B60]

It is not difficult to understand that some lncRNAs are necessary regulators during embryogenesis and organ differentiations. No matter what kinds of regulation modes are, they were involved in different biogenesis, and would cause more or less impacts on embryogenesis and organ differentiations. Besides, because of the tissue specificity, their aberrant expressions might be finally related to different human diseases.

Medical applications of lncRNAs in human diseases
=================================================

The best results of basic research are transforming the discoveries into diagnostic methods and therapeutic strategies for human diseases. Because of the tissue-specific characteristics of lncRNAs, they would be the next generation of biomarkers or targets for human diseases such as human cancer and cardiovascular diseases.

Biomarkers and therapy strategies for human cancers (Table [1](#T1){ref-type="table"})
--------------------------------------------------------------------------------------

lncRNAs, which isolated from tumor cells or circulating system, could provide readily-available, inexpensive and stable blood-borne diagnostics to more readily detect cancers and cancer subtypes[@B66]. Yang et al. analyzed eight kinds of lncRNAs in 240 patients with HCC and reported that highly upregulated in liver cancer (HULC) had a significant association with vascular invasion and was a positive factor for HCC overall survival and disease-free survival time [@B67]. They also reported that H19 was overexpressed in patients with hepatitis B [@B67]. Furthermore, they indicated that H19 and maternally expressed 3 (MEG3) were both considered to be risk factors for high alpha fetoprotein (AFP) level [@B67]. Tang J., et al have reported that compared with the traditional biomarkers of HCC (AFP), three lncRNAs (RP11-160H22.5, XLOC_014172 and LOC149086) might be the potential biomarker for the tumorigenesis prediction and XLOC_014172 and LOC149086 for metastasis prediction in the future [@B68]. Zhao et al., have reported that SPRY4 intronic transcript 1 (SPRY4-IT1) is an independent prognostic factor of overall survival in patients with urothelial carcinoma of the bladder (UCB) [@B69]. The work of Kristina P Sørensen.et al., firstly investigated the prognostic potential of lncRNA profiles for patients with breast cancer, which can distinguish metastatic patients from non-metastatic patients with sensitivity more than 90% and specificity of 64 to 65% [@B70].

Because of the heterogeneity of human cancer, the personalized medicine for human cancer has been proposed for many years, and the precision medicine has become the most important field for cancer research and treatment. However, the etiologies of human cancer are so complex that the results need to be transformed by different levels of clinical trials. Several strategies of cancer therapy have been developed presently.

Treating cancer by interference of RNA expression has developed as a treatment modality because growth-promoting lncRNAs could be inactivated through antisense technologies [@B66]. LncRNAs could also function as mRNA or miRNA sponges to inhibit the growth-promoting, pro-tumorigenic signaling pathway so that synthetically-engineered lncRNAs may be employed through replacement therapy to inhibit tumor cells [@B71]. Dextran nanoparticles can deliver chemotherapy to the nucleus, which may be used to attach cytotoxic agents to lncRNAs [@B66]. The plasmid DTA-H19 was designed to express a diphtheria toxin subunit controlled by the H19 promoter [@B72], [@B73], which could be injected into tumor and lead to a H19-dependent activation of diphtheria toxin within the tumor [@B45]. Another emerging method is to increase the activity of tumor suppressor by neutralizing the inhibitory effects of lncRNAs through antisense oligo nucleotides [@B66]. These compounds, which are directly taken up by cells, can be injected subcutaneously without any delivery vehicle [@B66]. They can cross endosomal membranes and enter the nucleus to inhibit PRC2 interaction with lncRNAs[@B46]. These compounds could also cross the blood brain barrier without a lipid carrier [@B66].

Biomarkers and therapy strategies in human cardiovascular diseases (Table [2](#T2){ref-type="table"})
-----------------------------------------------------------------------------------------------------

Although lncRNA in cardiovascular have not been researched as extensively and thoroughly as in human cancer, some research has indicated that lncRNA could be biomarkers for cardiovascular diseases. Kumarswamy et al., have validated mitochondrial lncRNA uc022bqs.1 (LIPCAR) as a novel biomarker of cardiac remodeling that predicts future death in patients with heart failure [@B74]. Myocardial infarction (MI) is another kind of important cardiovascular disease. Vausort et al., have verified about five kinds of lncRNAs as biomarkers for predicting the outcome of MI in about 414 patients, including hypoxia inducible factor 1A antisense RNA 2 (HIA1A-AS2), cyclin-dependent kinase inhibitor 2B antisense RNA 1 (ANRIL), potassium voltage-gated channel, KQT-like subfamily, member 1 opposite strand/antisense transcript 1 (KCNQ1OT1), myocardial infarction-associated transcript (MIAT), and MALAT1) [@B75]. Their results are summarized as follows: (1) HIA1A-AS2, CNQ1OT1 and MALAT1 were higher in patients with MI than in healthy volunteers (P\<0.01), while levels of ANRIL were lower in patients with MI (P=0.003); (2) compared with patients with non-ST-segment-elevation MI, patients with ST-segment-elevation MI had lower levels of ANRIL (P\<0.001), KCNQ1OT1 (P\<0.001), MIAT (P\<0.001), and MALAT1 (P=0.005) ; (3) levels of ANRIL were related to age, diabetes mellitus, and hypertension; (4) HIA1A-AS2 elevated in patients presenting within 3 h of chest pain onset than in patients presenting later; (5) ANRIL, KCNQ1OT1, MIAT, and MALAT1 were significant univariable predictors of left ventricular dysfunction as assessed by an ejection fraction ≤40% at 4-month follow-up; and (6) ANRIL and KCNQ1OT1 improved the prediction of left ventricular dysfunction by a model, including demographic features, clinical parameters, and cardiac biomarkers based on the multivariable and reclassification analyses [@B75].

Conclusions
===========

In summary, we have separately discussed several items of lncRNAs, including their definition and classification, their related research methods and strategies, their possible working mechanisms, their function during embryogenesis and organ differentiation, their significance in human cancer and cardiovascular diseases.

However, each section might have their limitations due to our unawareness of them. We could not make an exact definition for lncRNAs. And following with the discovery of new lncRNAs, we might be confronting with the difficulties from classifications. The present research methods could realize the interaction among RNA, DNA and protein, and provide important bioinformatics clues on basic research, we still need further techniques to reach a whole comprehension on lncRNA network mechanisms. We need not only learn about the real mechanisms of lncRNAs during embryogenesis and development, but also the novel changes in various kinds of diseases, and finally realize the destination of promoting human health by our knowledge.

This work was supported by Ningbo Municipal Natural Science Foundation (Grant Number: 2014A610219); Ningbo University Science Foundation (Grant Number: XYY15016); National Natural Science Foundation (Grant Number: 81602136).
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![lncRNA research strategies and methods. A. New species identification: Using methods, such as RNA-seq et al could discover new kinds of lncRNAs; B. Subcellular localization: FISH could help to analyze the location of target lncRNAs; C. Gain or loss of function: over-expression or knock down the lncRNA by lentivirus, shRNA or siRNA could help to learn the basic function of lncRNAs in cell; D. Molecular interaction: Using methods like RIP et al could analyze the interactions among RNA, DNA and protein; E. Bioinformatics analysis: Various kinds of databases could help to learn about the interested lncRNAs.](ijbsv13p0295g002){#F3}

![The working mechanisms of lncRNAs. The present known working mechanisms of lncRNAs might be only a part of its all functions, just like several hubbles among all blowing group. A. ceRNA function of lncRNA: circRNA compete binding with miRNA to prevent miRNA binding with target mRNAs; B. Enhancer on/off: lncRNAs transcribed from an enhancer region interact with enhancer-promoter contact to inhibit the transcription of the protein-coding gene; C. lncRNAs acting as scaffold linking different proteins interaction; D. lncRNAs binding with proteins to prevent their actions; E. lncRNAs recruiting proteins, such as chromatin- modifying complexes to specific target sites in the genome; F. lncRNAs loop formation and transcription of the associated gene; G. lncRNA transcripts evicting proteins from chromatin, such as pancRNA prevent DNMT from methylating DNA in their promoter region, thereby ensuring mRNA transcription; H. Stabilizing of mRNA: lncRNA recruiting proteins to preventing degradation.](ijbsv13p0295g003){#F2}

###### 

Working mechanisms and medical applications of lncRNAs in human cancer

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  LncRNA            Working mechanisms                                                                                                                                              Medical applications
  ----------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------
  ANRASSF1          form an RNA/DNA hybrid and recruits PRC2 to the RASSF1A promoter\[76\]                                                                                          **Biomarker :** breast cancer\[77\]

  ANRIL             chromatin remodeling: CDKN2A/B \[47\], Kruppel-like factor 2 (KLF2) and p21 locus by interacting with PRC1 and PRC2 \[24, 78\]                                  **Biomarker :**acute lymphoblastic leukemia (ALL) \[79\], ovarian cancer\[80\], non-small cell lung cancer (NSCLC)\[24\]

  H19               **1.**regulate IGF2 imprinting\[81\];\                                                                                                                          **Biomarker:** hepatocellular (HCC)\[67\]\
                    **2.**miR-675 precursor\[82-85\];\                                                                                                                              **Cancer therapy:** BC-819\[72\], BC-821, siRNA and anti-miR\* for lung cancer\[93\];\
                    **3.**ceRNA function by sponging of let-7\[86-88\], miR-138\[89\], miR-200a \[89\];\                                                                            **Cancer therapy:** double promoter toxin vector P4-DTA-P3-DTA for pancreatic cancer, ovarian cancer and HCC\[94-95\];\
                    **4.**chromatin remodeling by binding MBD1\[90\];\                                                                                                              **Cancer therapy:** DTA-H19 for unresectable pancreatic cancer\[66, 73\]
                    **5.**interact with Slug or EZH2 and\                                                                                                                           
                    regulate E-cadherin expression\[91-92\]                                                                                                                         

  MALAT1\           **1.**bind to unmethylated Pc2 promotes E2F1 SUMOylation, leading to activation of the growth-control gene program\[96\];\                                      **Biomarker:** predicting prostate cancer risk\[99\]
  (NEAT2)           **2.**ceRNA function by sponging of miR-145\[42\], miR-124\[43\], miR-205\[97\];\                                                                               
                    **3.**directly interact with Sp1 and LTBP3 promoter to increase expression of LTBP3 gene\[98\];\                                                                
                    **4.**bind to SFPQ and releasing PTBP2 from the SFPQ/PTBP2 complex\[50\]                                                                                        

  HOTAIR            **1.**chromatin remodeling chromatin remodeling HOXD gene locus\[100-101\];\                                                                                    **Biomarkers:** risk factors for high AFP level, HCC\[106\], breast cancer\[107\], colorectal cancer (CRC), gastric cancer (GC)\[108\]\
                    **2.**recruit and bind to PRC2\[102-103\] and epigenetically represses miR-34a\[104\];\                                                                         **Cancer therapy strategy:** Triple-negative breast cancer (TNBC)\[109\]
                    **3.**ceRNA function by sponging of miR-331-3p\[44\];\                                                                                                          
                    **4.**associate with the immunoprecipitated Ago2 (Argonaute2) complex, and cleaved by the Ago2 complex in the presence of miR-141\[105\].                       

  LincRNA-p21\      interact with hnRNP K leads to gene silencing and cell apoptosis\[51\]                                                                                          NA
  (TP53COR1)                                                                                                                                                                        

  PTENP1            **1.**ceRNA function by binding with miR-21\[110\], miRNA sponge of miR-17\[111\],miR-19b\[111\],miR-20a\[111\];\                                               **Biomarker:** GC\[111-112\]\
                    **2.**PTEN mRNA stability\[6\]                                                                                                                                  **Cancer therapy:** SB-BV hybrid vector for HCC therapy\[111\]

  PTENP1 asRNA\     **1.**the α isform suppress the expression of PTEN by localize on the PTEN promoter and interact with EZH2 and DNMT3a\[37\];\                                   NA
  (α,β,unspliced)   **2.**the β isform involved as a miRNA sponge mediated by PTENP1\[37\]                                                                                          

  BRAFP1            ceRNA\[46\]                                                                                                                                                     NA

  MEG3              **1.**interact with p53 by promoting p53 binding to GDF15 promoter\[113\];\                                                                                     **Biomarker:**risk factors for high AFP level, CRC \[116\], Tongue squamous cell carcinoma (TSCC) \[117\], GC \[118\]
                    **2.**dissociate the transcription factor SOX2 from the BMP4 promoter\[114\];\                                                                                  
                    **3.**ceRNA function by sponging of miR-21\[115\];                                                                                                              

  TERRA             promoted recruitment of lysine-specific demethylase 1 (LSD1) to unprotected telomeres and interacting with MRE11 (double strand break repair nuclease)\[119\]   NA

  PVT1              **1.**ceRNA function by sponging of miR-200 family\[120\];\                                                                                                     **Biomarker:** HCC, GC\[122, 124\], pancreatic cancer\[125\], CRC\[126\]
                    **2.**interact with NOP2 to protects it from degradation\[121\];\                                                                                               
                    **3.**associate with enhancer of zeste homolog 2 (EZH2) to repress p15 and p16\[122\];\                                                                         
                    **4.**recruit EZH2 to the large tumor suppressor kinase 2 (LATS2) promoter and represses LATS2 transcription\[123\]                                             

  HULC              **1.**activate ACSL1 promoter\[23\]\                                                                                                                            **Biomarkers :** HCC\[128\] , pancreatic cancer\[129\]
                    **2.**inhibit the miR-9 promoter\[23\];\                                                                                                                        
                    **3.**ceRNA function by sponging of miR-372 \[127\];                                                                                                            

  FER1L4            ceRNA function by sponging of miR-106-5p\[130-131\]                                                                                                             **Biomarkers:** diagnosis of CRC\[130\], GC\[132\]

  PCA3              form PRUNE/PCA3 double-strand RNA to control PRUNE\[133\]                                                                                                       **Biomarker :**prostate cancer\[134-135\]

  CCAT1             **1.**ceRNA function by sponging of let-7, miR-218-5p\[136\], miR-155\[137\], miR-490\[138\];\                                                                  NA
                    **2.**interact with CTCF and modulate chromatin conformation at these loop regions\[139\]                                                                       

  ATB               **1.**ceRNA function by sponging of miR-200c to mediate EMT\[140-141\];\                                                                                        NA
                    **2.**promote organ colonization of disseminated tumor cells by binding IL-11 mRNA, autocrine induction of IL-11, and trigger STAT3 signaling \[141\].          

  HNF1A-AS1         bind with DNMT1 to regulate cyclinD1\[142\]                                                                                                                     NA

  NKILA             interact with NF-KB/I-KB to form a stable complex , serving as NF-KB modulators to suppress metastasis\[143\]                                                   NA

  PANDAR            interact with NF-YA to pro-apoptotic genes\[144\]                                                                                                               **Biomarker :**hepatocellular carcinoma\[145\]

  PCAT-1            **1.**interact with myc\[146\];\                                                                                                                                **Biomarker:** esophageal squamous carcinoma (ESCC)\[148\], CRC\[149\]
                    **2.**repress BRCA2 3\'-UTR imparts a high sensitivity to PARP1\[147\]                                                                                          

  HOST2             ceRNA function by sponging of let-7b\[150\]                                                                                                                     NA

  GAPLINC           ceRNA function by sponging of miR-211-3p to compete with CD44\[151\]                                                                                            **Biomarker:**GC\[151\]

  ROR               **1.**ceRNA function by sponging of miR-145 \[152-153\]and miR-205\[154\];\                                                                                     NA
                    **2.**suppress p53 translation through direct interaction with the heterogeneous nuclear ribonucleoprotein I (hnRNP I)\[155\]                                   

  FAL1              interact with BMI1 and regulate a number of genes\[156\]                                                                                                        NA

  TARID             interact with TCF21 promoter and GADD45A to directs de-methylation of TCF21\[157\]                                                                              NA

  UCA               **1.**activate STAT3 and repress miR-143 to activate mTOR to regulate HK2\[158\];\                                                                              NA
                    **2.**interact with hnRNP1 to suppress p27 protein level\[159\]                                                                                                 

  TUG1              modulate HOXB7 to participating in AKT and MAPK pathways\[160\]                                                                                                 NA

  RUNXOR            utilize its 3\'-UTR terminal fragment to directly interact with RUNX1 promoter chromosomal translocation\[161\]                                                 NA

  SPRY4-IT1         interact with ZNF-703\[162\]                                                                                                                                    **Biomarkers:** urothelial carcinoma of the bladder\[69\], GC\[163\], prostate cancer\[164\], ESCC\[165\]
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Working mechanisms and medical applications of lncRNAs in human cardiovascular diseases

  LncRNA        Working mechanisms in cardiovascular diseases                                                                                                                     Medical application
  ------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------
  LIPCAR        NA                                                                                                                                                                **Biomarkers:**cardiac remodeling predicts future death in patients with heart failure\[74\]
  ANRIL         NA                                                                                                                                                                **Biomarkers:**significant univariable predictors of left ventricular dysfunction\[75\]
  KCNQ1OT1      NA                                                                                                                                                                **Biomarkers:** significant univariable predictors of left ventricular dysfunction\[75\]
  MALAT1        NA                                                                                                                                                                **Biomarkers:** significant univariable predictors of left ventricular dysfunction\[75\]
  MIAT          ceRNA: function by sponging of miR-150-5p\[166\]                                                                                                                  **Biomarkers:** significant univariable predictors of left ventricular dysfunction\[75\]
  MHRT          Sequesters Brg1 from its genomic DNA targets to prevent chromatin remodeling \[167\]                                                                              **Biomarkers :**myocardial infarction (MI)\[168\]
  UCA1          NA                                                                                                                                                                **Biomarkers:**Acute myocardial infarction (AMI) \[169\]
  LincRNA-p21   Binding with MDM2 and release MDM2 repression of p53 \[170\]                                                                                                      NA
  RNCR3         acts as a ceRNA, and forms a feedback loop with Kruppel-like factor 2 and miR-185-5p to regulate cell function, atheroprotective role in atherosclerosis\[171\]   NA
  ROR           promotes cardiac hypertrophy via interacting with miR-133\[172\]                                                                                                  NA
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